Armstrong Andrew J, Azad Arun A, Conduit Ciara, Haas Gabriel P, Bland Christopher, Davis Ian D
Duke Cancer Institute Center for Prostate & Urologic Cancers, Duke University, Durham, NC, USA.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Future Oncol. 2025 Jan;21(1):15-24. doi: 10.1080/14796694.2024.2408101. Epub 2024 Oct 15.
WHAT IS THIS SUMMARY ABOUT?: This summary includes information from the ARCHES and ENZAMET . Both studies looked at enzalutamide treatment for people with metastatic hormone-sensitive prostate cancer (known as mHSPC). In ARCHES, researchers compared the medications enzalutamide + androgen deprivation therapy (known as ADT) with + ADT. In ENZAMET, researchers compared enzalutamide + ADT with + ADT. Some people in ENZAMET also took enzalutamide with docetaxel (a treatment). In both studies, researchers wanted to find out if enzalutamide helps people with mHSPC live longer.
WHAT ARE THE KEY TAKEAWAYS?: In both studies, researchers found that people with mHSPC who took enzalutamide lived longer than people who did not. People who took enzalutamide also lived longer without their cancer getting worse. The results were mostly similar in groups of people dependingon when and where their cancer was found. Researchers did not find any new safety concerns.
WHAT WERE THE MAIN CONCLUSIONS?: People with mHSPC may benefit from long-term treatment with enzalutamide + ADT. They may also benefit from taking enzalutamide with other treatments, like docetaxel. It may be better for people with mHSPC to have enzalutamide treatment before their cancer gets worse, rather than waiting. These people and their doctors should carefully consider the benefits and risks of each treatment to make a joint decision for treating mHSPC. NCT02677896 (ARCHES), NCT02446405 (ENZAMET) (ClinicalTrials.gov).
本综述的内容是什么？：本综述包含来自ARCHES和ENZAMET研究的信息。这两项研究均着眼于恩杂鲁胺用于转移性激素敏感性前列腺癌（即mHSPC）患者的治疗。在ARCHES研究中，研究人员将恩杂鲁胺+雄激素剥夺疗法（即ADT）与[此处原文缺失一种治疗方案] + ADT进行了比较。在ENZAMET研究中，研究人员将恩杂鲁胺+ ADT与[此处原文缺失一种治疗方案] + ADT进行了比较。ENZAMET研究中的一些患者还将恩杂鲁胺与多西他赛（一种治疗方法）联合使用。在这两项研究中，研究人员都想弄清楚恩杂鲁胺是否有助于mHSPC患者延长生存期。
关键要点有哪些？：在两项研究中，研究人员均发现，接受恩杂鲁胺治疗的mHSPC患者比未接受该治疗的患者生存期更长。接受恩杂鲁胺治疗的患者在癌症未恶化的情况下生存期也更长。根据癌症的发现时间和部位分组，结果大多相似。研究人员未发现任何新的安全问题。
主要结论是什么？：mHSPC患者可能从恩杂鲁胺+ ADT的长期治疗中获益。他们也可能从恩杂鲁胺与其他治疗方法（如多西他赛）联合使用中获益。对于mHSPC患者而言，在癌症恶化之前接受恩杂鲁胺治疗可能比等待更好。这些患者及其医生应仔细考虑每种治疗的益处和风险，以便共同做出治疗mHSPC的决策。NCT02677896（ARCHES），NCT02446405（ENZAMET）（ClinicalTrials.gov）。
